Facioscapulohumeral Muscular Dystrophy clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 18 years and up
Study A083-02 is a multicenter, Phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE 083 in patients with FSHD to be conducted in two parts. Part 1 is open-label, dose-escalation and Part 2 is randomized, double-blind, and placebo-controlled.
Sacramento, California and other locations